Latest Regulatory News

Centrex Limited and its subsidiary Agriflex Pty Ltd have entered a Deed of Company Arrangement (DOCA) with PRL Group Limited set to acquire 100% of Centrex shares, pending court approval. An independent expert report values Centrex shares at nil on a liquidation basis, while mineral assets are valued at A$5.6 million.

Lloyds Banking Group reported a robust first half in 2025, with net income up 6%, strong lending growth, and a 15% increase in its interim dividend. The bank reaffirmed its 2025 guidance and expressed confidence in meeting ambitious 2026 targets.

The Foreign Investment Review Board has approved CoStar Group’s acquisition of Domain Holdings, clearing a major regulatory hurdle ahead of the shareholder vote scheduled for August 4.

PointsBet Holdings Limited has issued a Target’s Statement recommending shareholders accept MIXI Australia’s $1.20 per share all-cash takeover offer, highlighting a significant premium and rejecting a rival scrip bid from Betr Entertainment.

Wrkr Ltd reports sustained positive operating cash flow and strategic investments positioning it for growth despite an anticipated FY25 EBITDA loss. The company’s landmark deals and platform enhancements signal readiness for upcoming regulatory reforms.

Xstate Resources has pushed back the closing date of its public offer to early August, setting the stage for a potential ASX re-listing by late August following key approvals and asset acquisition.

DeSoto Resources has accelerated its exploration efforts with promising gold assay results in Guinea and initial rare earth drilling in Australia’s Northern Territory, supported by a strong cash position.

Santana Minerals reports a robust update to its Bendigo-Ophir Gold Project with a new Pre-Feasibility Study showing enhanced economics and streamlined mine design, alongside advancing regulatory approvals in New Zealand.

Zelira Therapeutics has locked in a $650,000 loan facility secured against its anticipated FY25 R&D tax rebate, aiming to accelerate its HOPE SPV clinical trial and strengthen working capital.

Alterity Therapeutics has published a peer-reviewed study introducing the MSA Atrophy Index, a novel MRI-based biomarker that enhances diagnosis and monitoring of Multiple System Atrophy, potentially transforming clinical trials and patient care.

Kinterra Capital has withdrawn its review application to the Takeovers Panel after increasing its offer for New World Resources, prompting the board to recommend acceptance and Central Asia Metals to exit the race.

Capricorn Metals has agreed to acquire Warriedar Resources in a court-approved all-share deal, expanding its Western Australian gold footprint and adding 2.3 million ounces gold equivalent to its resource base.